Is the CSL share price a buy after the coronavirus volatility?

Is the CSL Limited (ASX:CSL) share price a buy due to the coronavirus volatility? The healthcare giant has seen its share price fall 20%.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is down around 20% over the past month.

The healthcare giant hasn't been as affected as much as some of the other blue chip shares such as Commonwealth Bank of Australia (ASX: CBA) which is down around 33% over the past month.

CSL is now a lot bigger than CBA and I think it could stay like that. CBA is facing a number of uncertainties over the coming months with the economic disruption to most of the country.

But I don't think CSL is going to be as affected as much or as long as the banks, or most other blue chips in my opinion.

CSL hasn't yet given an update with the coronavirus spreading significantly across the western world.

In the half-year result the company upgraded its FY20 profit outlook so that it was in the range of approximately US$2.11 billion to US$2.17 billion, which would be growth of 10% to 13%.

CSL has previously said that because this coronavirus is quite different to the influenza virus it's not a core area of focus for CSL or Seqirus, though it is looking into "possible adjacencies in expertise, technologies and facilities that might be able to contribute to the global effort."

It has partnered with the University of Queensland's COVID-19 vaccine development program. It will provide technical expertise as well as a donation of Seqirus' proprietary adjuvant technology to their pre-clinical development program. Adjuvants are used in vaccines to create a stronger immune response and to speed vaccine production and output. The University of Queensland will use the adjuvant to test the viral protein they are developing with their molecular clamp technology.

However, the research program is just starting and it will be some months before the success of the program will be known.

Foolish takeaway

CSL is trading at 28x FY22's estimated earnings. I think that's how far ahead you need to look before the global economy may be back to normal. I think the combination of lower share price and lower interest rate makes CSL a decent long-term buy today. But I think there are shares out there with better growth prospects.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a man with a wide, eager smile on his face holds up three fingers.
Growth Shares

3 reasons this ASX growth stock is a top buy

Goldman Sachs thinks this stock could generate big returns.

Read more »

A man stands with arms crossed in front of a giant shadow of a body builder representing ASX small-cap stocks.
Growth Shares

3 of the best growth-focused ASX shares to buy in July

These ASX stocks look like potential market-beaters to me.

Read more »

happy investor, share price rise, increase, up
Growth Shares

These top ASX 200 growth shares could rise 20% to 45%

These growth stocks have been named as buys by brokers and tipped to rise strongly.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Growth Shares

5 ASX growth shares that could rise 10% to 40%

Brokers have put buy ratings on these stocks recently. Let's see what they are expecting from them.

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 top ASX growth shares that could rise ~10% to 25%

Analysts are tipping big returns from these growth stocks.

Read more »

A woman shows her phone screen and points up.
Growth Shares

I'd buy these 2 top ASX growth shares in a heartbeat

Here are two stocks I’m bullish about.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Growth Shares

3 fantastic ASX growth shares to buy in July

Analysts are feeling very bullish about these stocks. But why?

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Growth Shares

Here's why brokers say these ASX growth shares are top buys

Big returns could be on the cards for buyers of these shares.

Read more »